Trials / Completed
CompletedNCT01776606
Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 247 (actual)
- Sponsor
- Revance Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of botulinum toxin type A compared to placebo control for the treatment of moderate to severe crow's feet lines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Botulinum Toxin Type A | Botulinum Toxin Type A, Dose A; dose applied to the lateral canthal lines |
| DRUG | Placebo | Placebo, Dose B; dose applied to the lateral canthal lines |
Timeline
- Start date
- 2012-12-01
- Primary completion
- 2013-05-01
- Completion
- 2013-05-01
- First posted
- 2013-01-28
- Last updated
- 2014-05-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01776606. Inclusion in this directory is not an endorsement.